{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:44:53Z","timestamp":1787942693738,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00345-019-02850-3","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T15:04:38Z","timestamp":1561647878000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie\u2019s disease: a review of the literature"],"prefix":"10.1007","volume":"38","author":[{"given":"Thomas A.","family":"Masterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"issue":"3","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A et al (2015) Peyronie's disease: AUA guideline. J Urol 194(3):745\u2013753","journal-title":"J Urol"},{"issue":"2","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11930-015-0045-y","volume":"7","author":"AN Bilgutay","year":"2015","unstructured":"Bilgutay AN, Pastuszak AW (2015) Peyronie's disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep 7(2):117\u2013131","journal-title":"Curr Sex Health Rep"},{"issue":"1","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M et al (2013) Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199\u2013207. \nhttps:\/\/doi.org\/10.1016\/j.coal.2011.01.004","journal-title":"J Urol"},{"issue":"4","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG et al (2019) Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol 201(4):777\u2013782","journal-title":"J Urol"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","volume":"119","author":"K Wymer","year":"2018","unstructured":"Wymer K et al (2018) Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie\u2019s disease. Urology 119:109\u2013114","journal-title":"Urology"},{"issue":"4","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bju.14410","volume":"122","author":"A Cocci","year":"2018","unstructured":"Cocci A et al (2017) Fully coupled two-phase flow and poromechanics modeling of coalbed methane recovery: Impact of geomechanics on production rate. Journal of Natural Gas Science and Engineering 45(4):680\u2013687","journal-title":"BJU Int"},{"issue":"1","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK et al (1993) Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 149(1):56\u201358","journal-title":"J Urol"},{"issue":"4","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI et al (2015) Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650\u2013656","journal-title":"BJU Int"},{"issue":"6","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P (2006) An analysis of the natural history of Peyronie's disease. J Urol 175(6):2115\u20132118 (discussion 2118)","journal-title":"J Urol"},{"issue":"4","key":"2850_CR10","first-page":"e681","volume":"189","author":"IKL Goldstein","year":"2013","unstructured":"Goldstein IKL, Mills J et al (2013) Clinical evaluation of treatment of Peyronie\u2019s disease with collagenase clostridium histolyticum: analysis of penile curvature deformity by duration of disease and plaque calcification. J Urol 189(4):e681\u2013e682","journal-title":"J Urol"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/j.juro.2015.02.2763","volume":"193","author":"LA Levine","year":"2015","unstructured":"Levine LA, Gelbard MK, Tursi JP et al (2015) Outcomes associated with collagenase clostridium histolyticum for Peyronie\u2019s disease by duration of disease. J Urol 193:e96","journal-title":"J Urol"},{"issue":"5","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13932","volume":"120","author":"A Abdel Raheem","year":"2017","unstructured":"Abdel Raheem A et al (2017) Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int 120(5):717\u2013723","journal-title":"BJU Int"},{"issue":"5","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.21037\/tau.2017.07.27","volume":"6","author":"L Diao","year":"2017","unstructured":"Diao L et al (2017) Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease. Transl Androl Urol 6(5):894\u2013898","journal-title":"Transl Androl Urol"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J et al (2017) Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease. Urology 100:125\u2013130","journal-title":"Urology"},{"issue":"4","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/andr.12497","volume":"6","author":"M Capece","year":"2018","unstructured":"Capece M et al (2018) Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. Andrology 6(4):564\u2013567","journal-title":"Andrology"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","volume":"119","author":"K Wymer","year":"2018","unstructured":"Wymer K et al (2018) plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease. Urology 119:109\u2013114","journal-title":"Urology"},{"issue":"4","key":"2850_CR17","first-page":"e682","volume":"189","author":"BLG Hertzman","year":"2013","unstructured":"Hertzman BLG, Tursi J, Hobson S, Kaminetsky J (2013) Subgroup analysis of curvature deformity severity and symptom bother improvement in patients with Peyronie\u2019s disease being treated with collagenase Clostridium histolyticum in clinical studies. J Urol 189(4):e682","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02850-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:11:48Z","timestamp":1593040308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02850-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors TM and RR are recipients of an investigator-initiated research grant from Endo Pharmaceuticals. University of Miami is the recipient of a fellowship grant from Endo Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is a review of the literature and did not directly involve patients. No additional informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}